Patients, who are resistant to Gleevec drug can now be treated with dasatinib, which seems to regulate intolerance and complications of chronic myeloid leukemic patients - studies published in NEJM finds.
In the phase I clinical trials dasatinib overcome Gleevec resistance in about 68 of 84 patients studied - study leader, HHMI investigator Charles L. Sawyers, and colleagues at UCLA's Jonsson Comprehensive Cancer Center, reported.
People in all 3 stages of the disease such as chronic phase, the accelerated phase, and blast crisis respond to the new drug quite possibly, Sawyers says.
Sawyers said, 'Drug-related mutations are better understood by the application of experimental drug, dasatinib to subjects and even individual patient's mutation type were easily studied by scientists at Bristol-Myers Squibb'.
'How drug target mutation take place and whether molecular explanation of drugs has any role to play in it' all studied by the scientists, showing improvements in structural biology studies.
Due to being as a 'sloppier inhibitor' meaning - does not hold its target to such tight structural constraints, dasatinib differs from the drug Gleevec.
Sawyers added dasatinib proves its value to overcome kinase resistance in managing cancer patients and also keep rooting in other fields of medicine like molecular oncology and structural biology.